Contribute Try STAT+ Today

Good morning, everyone, and how are you today? Like many others, we are forging ahead despite the disturbing events in the U.S. Capitol. Sorry to say, this was easy to predict (a few years ago, in fact). But there is work to be done, so time to get cracking. We are firing up the coffee kettle and brewing another cup of stimulation — our choice today is French vanilla. Feel free to join us. Meanwhile, as always, we have assembled a few tidbits for you to digest. We hope today is productive and you conquer the world. Stay in touch and stay safe — wear a mask. …

The leaders of Operation Warp Speed will continue working on the vaccine rollout during the Biden administration, but Moncef Slaoui, the chief scientific adviser to the government’s vaccine accelerator, will not stay on for long, STAT tells us. Slaoui will take on a reduced role as a consultant for four to six weeks before departing, while Gen. Gustave Perna, Operation Warp Speed’s chief operating officer, said he has not been told whether he will remain at the initiative.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.